Reason for request
Inclusion on the list of medicines reimbursed by National Health Insurance and approved for use by hospitals.
Clinical Benefit
| Substantial |
The actual benefit of RANEXA in this indication is substantial. |
Clinical Added Value
| no clinical added value |
RANEXA should be used only by patients with stable angina that is inadequately controlled or who are intolerant to betablockers and/or calcium channel blockers.
Given the data available, RANEXA does not provide any improvement in actual benefit (IABV) in the management of these patients. |
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
CKrCGUk8113dgMg9
